上海醫藥(02607.HK)旗下鹽酸胺碘酮注射液獲內地批准生產
上海醫藥(02607.HK)(601607.SH)公布,其下屬全資子公司上藥第一生化的鹽酸胺碘酮注射液收到國家藥監局頒發的《藥品註冊證書》(證書編號:2024S00255),該藥品獲得批准生產。
鹽酸胺碘酮注射液主要用於治療不宜口服給藥時嚴重的心律失常,最早由賽諾菲研發,於1976年在法國上市。2022年1月上藥第一生化就該藥品向國家藥監局提出註冊上市申請並獲受理。截至目前,公司針對該藥品已投入研發費用約720萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.